This study analyzes the market for drug delivery systems in the US. It presents historical demand data for the years 2000, 2005 and 2010, and forecasts for 2015 and 2020 by material (e.g., monoclonal antibodies, synthetic and natural polymers, nanosized particles); type (e.g., oral, parenteral, inhalation, transdermal, implantable); and application. The study also considers market environment factors, details industry structure, evaluates company market share and profiles leading industry players.
US demand to rise 7.2% annually through 2015
US demand for drug delivery products is forecast to expand 7.2 percent annually to $133 billion in 2015. The best growth opportunities will emerge in specialized pharmaceutical formulations and administration devices that advance the nature of therapy for autoimmune conditions, cancer, heart disease, neurological disorders and other debilitating health problems. Included in this group are human monoclonal antibodies, polymer encapsulated nanomedicines and transdermal patches for breakthrough pain management. Infusion products and parenteral delivery devices with improved safety, infection prevention and ease-of-use features will also fare well in the marketplace. Among these devices are retractable syringes, needleless injectors, premixed IV systems and smart infusion pumps. Based on the complex nature of therapy and the high frequency of dosing requirements, central nervous system, respiratory and hormonal indications will command the largest and fastest growth by drug delivery products.
Chewable and orally disintegrating tablets to see good growth
Demand for oral drug delivery products will increase 4.3 percent annually to over $52 billion in 2015. Controlled-release formulations will command the largest share of sales, but will lose some growth momentum due to patent expirations on several large-selling sustained-release therapies. Chewable and orally disintegrating tablets, nanoparticulate medicines and transmucosal therapies will realize faster growth in demand spurred by new product introductions and the high valueadded nature of indications served.
Monoclonal antibodies to pace parenteral products
Demand for parenteral drug delivery products will reach $54.7 billion in 2015, up eleven percent annually from 2015. Monoclonal antibodies will lead gains as advances in biotechnologies contribute new and improved therapies for autoimmune disorders, cancer and various rate debilitating diseases. Polymer-encapsulated medicines will also see fast rising demand based on contributions to the improved bioavailality and reduced toxicity of advanced parenteral compounds. Safety-engineered prefillable syringes and IV catheters, along with bag/ vial infusion systems, will command the best growth opportunities among parenteral infusion products and delivery devices due largely to infection prevention advantages.
Patches to lead gains among other drug delivery systems
Other drug delivery products will post demand of $26.1 billion in 2015, up 6.6 percent annually from 2010. Prefilled dry powder and metered dose inhalers will retain the largest share of sales, spurred largely upward trends in prevalence of asthma and chronic obstructive pulmonary disease (COPD). Less favorably, growth opportunities for these devices will decelerate as patent expirations open up several widely prescribed inhalation therapies, including sales leader ADVAIR, to generic competition. Led by new next-generation drug-eluting stents with thinner struts and enhanced safety profiles, implantable drug delivery systems will generate rebounding demand in angioplasty procedures, reversing a recent sharp sales drop. Transdermal patches will realize the fastest growth among other drug delivery systems as new therapies for breakthrough pain and various central nervous system disorders replace less effective oral medicines.
Profiles for US Competitors such as Abbott Labs, Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, Medtronic, Pfizer and others.
This comprehensive study examines the US market for drug delivery products. The discussion covers specialized dosage formats and devices that improve the safety, effectiveness and/or administration ease of pharmaceutical, biological and other therapeutic agents. For the purposes of analysis, this study divides drug delivery products into three major groups:
- oral (controlled-release, chewable, orally disintegrating, polymerbased and transmucosal)
- parenteral (monoclonal antibodies, injectors and related devices, nanoparticulate formulations, and premixed IV solutions)
- other (inhalation, implantable and transdermal)
Unless otherwise indicated, all statistics and forecasts represent demand for drug delivery products stated in current US dollars. The term “demand” is equivalent to “value of consumption” or “manufacturers’ sales” and correlates to the value of domestic production plus imports minus exports. Historical data (2000, 2005, 2010) and forecasts for 2015 and 2020 are provided for drug delivery products by type and application. It should be noted that the value of demand presented for controlled-release and other specialized dosage formats as well as for implantable products, prefilled inhalers, premixed IV containers and transdermal patches is based on manufacturers’ sales of finished products and includes the cost of enclosed medication. By contrast, the value of demand presented for prefillable and hypodermic syringes, IV catheters, and related parenteral delivery devices reflects sales of devices without medication.
Corporate information and data appearing in Section IX, “Industry Structure,” are based on estimates derived from published company reports and personal interviews with competitors, industry experts and sources within the companies themselves. Macroeconomic indicators were taken from The Freedonia Group Incorporated Consensus Forecasts dated August 2011. The sum of individual components appearing in the study tables may not always add to the apparent total due to independent rounding. All ratios were calculated on the basis of unrounded numbers.
Information and data related to the US market for drug delivery products were obtained from a variety of primary and secondary sources including government and trade associations, industry participants, online databases and other Freedonia studies. Primary information was gathered through consultations with officers and marketing/technical personnel of participating companies and other industry specialists. Secondary and background information were obtained from several medical and pharmaceutical publications including American Journal of Health-System Pharmacy, Drug Development & Delivery, Drug Discovery & Development, Drug Topics, Pharmaceutical Technology and R&D Directions. Corporate annual reports, SEC Form 10-K and 20-F filings, product literature, and other company information were also used extensively in framing the industry environment and as input for market size assessments.